Ashwagandha for Perimenopause: The Cortisol-Sleep Nexus

Ashwagandha root extracts contain withanolides (the marker compound class — KSM-66 is standardized to ≥5% withanolides, Sensoril to ≥10%), withanosides, alkaloids, and other constituents. The mechanistic consensus frames ashwagandha as an HPA-axis modulator rather than a direct sedative. Preclinical and clinical work points to GABAergic modulation (partly explaining the sleep effect), reductions in serum cortisol (particularly the morning peak), and broader effects on thyroid hormones and DHEA-S. The clinical translation is consistent: ashwagandha tends to flatten the cortisol curve without producing benzodiazepine-style sedation or tolerance. This distinction matters for the peri-sleep cluster specifically. The wired-tired pattern is not benzodiazepine-deficiency — it is HPA-axis dysregulation overlaid on a hormonal substrate that is itself changing. An adaptogen that modulates cortisol without adding sedative burden is mechanistically a better fit than escalating to Z-drugs for women who don't want the dependence-and-tolerance profile of pharmaceutical sedatives. The evidence for this fit is not perimenopause-specific but it is mechanism-coherent.

The single most important decision in ashwagandha shopping for the peri-sleep cluster is not which brand you buy — it's whether the label specifies KSM-66 or Sensoril as the standardized extract. Every credible cortisol-and-sleep RCT in this category used one of those two named extracts. "Ashwagandha root powder" or "ashwagandha extract" without a named standardized extract is the canonical red flag — it could mean anything from a full-spectrum root powder to a low-withanolide product, and dose translation breaks down. Extract type matters. KSM-66 is a root-only extract standardized to ≥5% withanolides; Sensoril is a root-and-leaf extract standardized to ≥10% withanolides. They are not directly equivalent in dose: Sensoril is typically dosed at 125-250mg/day; KSM-66 at 240-600mg/day. The Lopresti 2019 RCT (PMID 31517876) used KSM-66 240mg; the Salve 2019 RCT (PMID 32021735) tested 250mg and 600mg; the Langade 2019 RCT (PMID 31728244) used ashwagandha root extract at 600mg. Timing matters. Ashwagandha can be taken morning, split, or evening. For the peri-sleep cluster specifically, the evening or split-dose pattern aligns better with the cortisol-curve-flattening mechanism — taking ashwagandha at the same time the wired-tired pattern peaks. Many women find a single 600mg evening dose works well; others prefer 300mg morning + 300mg evening (the Jarrow titration path). Duration matters. Every credible RCT used at least 6 weeks. The Lopresti 2019 trial ran 60 days. The Langade 2019 trial ran 8 weeks. Plan a 6-week minimum and use a daily diary (sleep onset 0-3, 3 a.m. waking yes/no, daytime energy 0-3) to make assessment honest. Think about the stack, not the single bottle. For peri-sleep specifically, ashwagandha works alongside — not instead of — the basics: regular exercise, magnesium glycinate, sleep regularization, addressing thyroid and iron status. Many women find correcting a missing basic (ferritin under 50, TSH out of range) does more for sleep than any single adaptogen. Food-first note: supplementing ashwagandha does not replace addressing thyroid, iron, or vitamin D deficiencies that often co-present with perimenopausal sleep complaints. Get the basic labs (CBC, ferritin, TSH, free T4, free T3, vitamin D, B12) before assuming an adaptogen is the answer. Get a sleep apnea evaluation if loud snoring, witnessed apneas, or severe daytime sleepiness apply.